Prothena Corporation plc (PRTA) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 28 analysts112.8% Below Target
PRTA trades 112.8% below Wall Street's consensus target of $19.00.
Current Price$8.93
Average Target$19.00
Low$19.00
Median$19.00
High$19.00
Analyst Target Range
Forward P/E191.2x
(High Premium)
PEG Ratio—
Implied Growth+101.7%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PRTA achieves its forward estimates and maintains a stable P/E multiple of 191.2x. This scenario reflects the blended consensus of 28 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PRTA Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Prothena Corporation plc (PRTA) has a Wall Street consensus price target of $19.00, based on estimates from 28 covering analysts. With the stock currently trading at $8.93, this represents a potential upside of +112.8%. The company has a market capitalization of $468M.
Analyst price targets range from a low of $19.00 to a high of $19.00, representing a 0% spread in expectations. The median target of $19.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PRTA trades at a trailing P/E of -2.0x and forward P/E of 191.2x. Analysts expect EPS to grow +101.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+46.3%
Industry Consensus
Avg Forward P/E
26.1x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $2.7B | $27.44 | $48.36 | +76.2% | Buy | — | 33 |
 IONSIonis Pharmaceuticals, Inc. | $12.2B | $74.12 | $109.44 | +47.7% | Buy | — | 32 |
 ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
 BIIBBiogen Inc. | $29.0B | $196.58 | $218.32 | +11.1% | Buy | 13.5x | 48 |
 REGNRegeneron Pharmaceuticals, Inc. | $63.4B | $609.94 | $836.00 | +37.1% | Buy | 13.1x | 48 |
 ARVNArvinas, Inc. | $495M | $7.67 | $14.75 | +92.3% | Buy | — | 26 |
 NTLAIntellia Therapeutics, Inc. | $1.8B | $15.67 | $26.13 | +66.8% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.5B | $34.14 | $48.00 | +40.6% | Buy | — | 27 |
PRTA — Frequently Asked Questions
Quick answers to the most common questions about buying PRTA stock.
What is the PRTA stock price target for 2026?
The consensus Wall Street price target for PRTA is $19, representing 112.8% upside from the current price of $8.93. With 28 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is PRTA a buy, sell, or hold?
PRTA has a consensus rating of "Buy" based on 28 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 112.8% upside from current levels.
Is PRTA stock overvalued or undervalued?
At a forward P/E of 191.2206x, PRTA trades at a premium valuation. The consensus price target of $19 (112.8% upside) suggests analysts still see growth justifying the multiple.
How high can PRTA stock go?
The most bullish Wall Street analyst has a price target of $19 for PRTA, while the most conservative target is $19. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PRTA stock?
PRTA is heavily covered by Wall Street, with 28 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PRTA stock forecast?
The 12-month PRTA stock forecast based on 28 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $19 (bear case) to $19 (bull case). The median consensus rating is "Buy".
What is PRTA's forward P/E ratio?
PRTA trades at a forward P/E ratio of 191.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PRTA stock?
Wall Street analysts are very optimistic on PRTA, with a "Buy" consensus rating and $19 price target (112.8% upside). 20 of 28 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PRTA price targets vary so much?
PRTA analyst price targets range from $19 to $19, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare